ASX:ILAPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
ISLAND PHARMACEUTICALS ORD
$0.370
+$0.005 (+1.37%)
Day Range
$0.370 - $0.375
52 Week Range
$0.120 - $0.630
Volume
53.66K
Avg Volume (10D)
205.34K
Market Cap
$93.96M
Price Chart
Market Statistics
Open$0.375
Previous Close$0.365
Day High$0.375
Day Low$0.370
52 Week High$0.630
52 Week Low$0.120
Valuation
Market Cap93.96M
Shares Outstanding253.96M
Price to Book13.91
Trading Activity
Volume53.66K
Value Traded19.94K
Bid$0.370 × 3,591
Ask$0.395 × 9,090
Performance
1 Day1.37%
5 Day0.00%
13 Week-19.57%
52 Week131.25%
YTD-13.95%
Technical Indicators
RSI (14)44.56
50-Day SMA$0.395
200-Day SMA$0.352
Latest News
Biotechnology
Island Pharma Expands Antiviral Pipeline with Burnet Institute Collaboration and NHMRC Funding
Island Pharma expands antiviral pipeline with Burnet Institute; NHMRC grant of over $780k to back ISLA-101, accelerating Galidesivir MVD program.
1 min read
Biotechnology
Island Pharma Partners with USAMRIID and Geneva Foundation for Galidesivir under FDA Animal Rule
Island Pharma signs a 3-year CRADA with USAMRIID and Geneva Foundation to fast-track Galidesivir for Marburg under FDA Animal Rule, eyeing NDA.
1 min read
Biotechnology
Island Pharmaceuticals Raises $9m to Fund Clinical Development as FDA Approves Galidesivir Pathway
Island Pharmaceuticals (ASX: ILA) secures FDA Animal Rule path for galidesivir and $9m funding to fast-track two-stage trials and US govt procurement potential.
1 min read
Biotechnology
Island Pharmaceuticals and Texas Biomed to Conduct Non-Human Primate Studies Using Antiviral Drug Galidesivir
Island Pharmaceuticals (ASX: ILA) has secured a master service agreement with Texas Biomedical Research Institute to support the development of lead antiviral molecule galidesivir.
1 min read